Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | STAT1 | P42224 | 1/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | IKBKB | O14920 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12562445 | 0.89 | ALDH1A1 (0.80) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL6100788 | 0.89 | ALDH1A1 (0.80) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL4657890 | 0.87 | CDK8 (0.76) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL8242540 | 0.85 | ALDH1A1 (0.74) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL5229346 | 0.85 | CDK8 (0.74) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL8242756 | 0.85 | ALDH1A1 (0.74) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL4657854 | 0.84 | CDK8 (0.73) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL17485804 | 0.83 | ALDH1A1 (1.00) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL4659275 | 0.82 | CDK8 (0.70) | CDK8ALDH1A1CDK19HTTKDM4E | |
| SCHEMBL4658096 | 0.81 | CDK8 (0.68) | CDK8ALDH1A1CDK19HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398749-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398680-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-10272069-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190111034-A1 | COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS | Apriligen, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
| US-10154992-B2 | Compounds and methods for treating HIV infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-18 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2892525-B1 | METHODS OF TREATING MUSCULAR DYSTROPHY | UNIV NEVADA RENO (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1968954-A | Thienopyridine Derivatives | SANKYO CO (JP) | 2007-05-23 | — | — | CN | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | CDK8 2499/4885ALDH1A1 1271/4885CDK19 4207/4885 |
| US-10272069-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-10398680-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-10154992-B2 | Compounds and methods for treating HIV infection | CD4, CCR5, MMP8 | CDK8 1366/4885ALDH1A1 482/4885CDK19 3399/4885 |
| US-10398749-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | CDK8 2516/4885ALDH1A1 1400/4885CDK19 4179/4885 |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-20190111034-A1 | COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS | CDK9, CDK8, CDK18 | CDK8 2/4885ALDH1A1 4061/4885CDK19 4/4885 |
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | CDK8 2528/4885ALDH1A1 342/4885CDK19 4195/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | CDK8 2017/4885ALDH1A1 1073/4885CDK19 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.